BUSINESS

Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?

January 4, 2019
While Takeda Pharmaceutical drew global headlines in FY2018, striking a mega deal to catapult it into the top 10 big pharma list, FY2019 might become the year for Daiichi Sankyo. It could clinch US FDA nods for three new cancer drugs…

To read the full story

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…